Chapter 9 - Arterial Hypertension in pregnancy

Epidemiology

The hypertensive syndromes of pregnancy cause expressive maternal and fetal morbidity and mortality. There is no accurate information on the incidence of preeclampsia (PE), but it is estimated to affect 4% of gestations. In Brazil, the incidence of PE is 1.5%, while the incidence of eclampsia is 0.6%. More developed areas have an incidence of eclampsia of 0.2%, with a maternal death rate of 0.8%, while for less favored regions those indices are 8.1% and 22%, respectively.

A population-based study shows AH in 7.5% of the gestations in Brazil, with 2.3% of PE and 0.5% of superimposed PE.

Arterial hypertension during pregnancy accounts for 20% to 25% of all causes of maternal death, and data from SUS show a trend towards stagnation.

Classification

This guideline recommends the American College of Obstetricians and Gynecologists’ (ACOG) classification of hypertension in pregnancy1 (Chart 1). (GR: IIb; LE: C).

Concept and diagnosis criteria

Arterial hypertension in pregnancy is defined as the presence of SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg, considering the fifth Korotkoff sound, confirmed by another measurement after 4 hours. For BP measurement, the patient should be ideally sitting, or, alternatively, in the lateral decubitus position. Proteinuria is considered: a) protein ≥ 300 mg in 24-hour urine; b) urine albumin/creatinine ratio (UACR) ≥ 0.3 mg/mg in an isolated sample; c) positive reagent strip test in at least two samples (quantification is suggested).

Preeclampsia is defined as the presence of AH after the 20th gestational week, associated with significant proteinuria, the absence of significant proteinuria, the diagnosis can be based on the presence of: headache, blurred vision, abdominal pain, low blood platelet count (< 100,000/mm³), elevation of liver enzymes (twice the baseline level), kidney impairment (creatinine > 1.1 mg/dL or twice the baseline level; persistent epigastric or right hypochondrial pain; acute kidney injury (AKI - creatinine > 1.1 mg/dL or twice the baseline level); pulmonary edema; visual or cerebral symptoms.5

Preeclampsia prevention

Regarding PE prevention, there is no unequivocally effective strategy for all pregnant women. Calcium supplementation (> 1 g/day) is not recommended for pregnant women with normal intake of that ion4 (GR: III; LE: A), but to those with low calcium intake and at intermediate and increased risk for PE.a (GR: I; LE: A). Low doses of acetylsalicylic acid (75-150 mg/day) at the end of the first gestational trimester can be useful for primary prevention of PE in pregnant women at intermediate and increased risk for PE.5,6 (GR: IIa; LE: B). That use, however, is not recommended in the absence of risk.5 (GR: III; LE: A). Calcium supplementation (> 1 g/day) is associated with a reduction in the risk for PE, prematurity and a lower risk of gestational-hypertension-related death, particularly in women with a low-calcium diet (< 600 g).6

For women at risk for PE, clinical trials have suggested a significant protective effect of the daily acetylsalicylic acid use.1 Low acetylsalicylic acid doses reduce the risk of PE by 17%, with a decrease in the fetal death risk of 14% and in the prematurity risk of 8%. Daily doses of 75-150 mg seem safe.6 Acetylsalicylic acid at low doses should be considered for primary prevention of women at high risk and should be initiated at the end of the first trimester.9

Nonpharmacological treatment

For persistent AH > 150 mm Hg for more than 15 minutes, NPT alone should not be used to prevent irreversible neurological damage.10 (GR: III; LE: B). Systolic BP > 155 mm Hg, especially > 160 mm Hg, is detected immediately before stroke.11 Severe diastolic AH (DAH: > 105 or 110 mm Hg) does not develop before most strokes of pregnant women with severe PE.11 To avoid maternal deaths, SBP > 150-160 mm Hg should indicate urgent treatment.12

Relative rest at hospital or day-hospital with monitoring is suggested for PE. (GR: Ia; LE: B). Hospitalization should be indicated to pregnant patients with severe AH. (GR: I; LE: B). A systematic review has shown no difference in outcomes between strict rest and relative rest for pregnant women with AH and proteinuria. Relative rest at hospital, as compared with routine house activity, reduces the risk for severe AH; however, data do not support a clear recommendation. Rest is not routinely indicated for gestational hypertension.13 Prenatal care units and hospitals have similar clinical outcomes for mothers and newborns, but women might prefer day-hospitals.14

Although there is no indication for specific care during hospitalization, maternal and fetal monitoring is required. Blood pressure should be periodically measured, with daily weight and diuresis assessment, and patients should be instructed about premonitory signs. Laboratory tests, such

Chart 1 – Classification of hypertension in pregnancy.

| Preeclampsia – Eclampsia |
|--------------------------|
| Chronic AH (any etiology) |
| Chronic AH with overlapping PE |
| Gestational hypertension |
as hemogram with platelet count, liver enzymes, uric acid, creatinine and proteinuria, should be performed once to
twice a week. Fetal follow-up comprises assessment of
growth, movements, well-being and biophysical profile, as
well as US.

**Expectant management**

Expectant management is not recommended after the 36th
gestational week for women with gestational hypertension.15
(GR: III; LE: B). Expectant management is suggested between the
34th and 36th gestational weeks for stable women, without clinical worsening or severe hypertension.16 (GR:
IIa; LE: B). Premature delivery for patients with PE can be
associated with decreased mortality. The ideal delivery time,
before the 32nd-34th weeks, is a dilemma because of the
uncertainty in the balance between maternal safety (end of
pregnancy) and fetal maturity (expectant).17 After the 34th
week, survival is high and the baby and placenta delivery is
effective in developed countries.17

The HYPITAT study has compared delivery induction
versus expectant monitoring for severe AH or mild PE after the 36th week.15 Women in the intervention group had a
29% lower risk of worse maternal outcome, without affecting neonatal outcome, suggesting that expectant treatment after 36 weeks is not indicated.15 In the HYPITAT-II study, with non-severe AH between the 34th and 37th weeks, expectant management increased maternal risk as compared to immediate delivery, but decreased the occurrence of neonatal respiratory distress syndrome. In that situation, immediate delivery is not justified, and expectant monitoring until the clinical situation worsens should be considered.16

**Pharmacological treatment**

Urgent pharmacological treatment is indicated in severe AH (SBP > 155-160 mm Hg)10,11 and presence of premonitory signs. (GR: I; LE: B). The treatment of severe AH in emergency situations can be performed with intravenous (IV) hydralazine (5 mg, repeat 5-10 mg IV every 30 minutes until the maximum of 20 mg). In exceptional situations, such as acute pulmonary edema (APE) and refractory severe SAH, the use of sodium nitroprusside (SNP) should be the preferential option for urgent BP
decrease. (GR: III; LE: B). Oral administration of rapid-acting nifedipine (5 mg every 30 minutes) is an alternative, but associated complications have been reported.19 Although sublingual nifedipine is not indicated in other forms of hypertensive crisis (HC), it is an alternative in gestational hypertension. Its use for hypertensive emergency (HE), however, has been considered bad practice, harmful to the patient in a report by the São Paulo Regional Medical Board.20

Pharmacological treatment should be initiated whenever
BP is > 150/100 mm Hg,12 aiming at maintaining it 130-
150/80-100 mm Hg. (GR: IIa; LE: B). For stable patients with
PE, not requiring immediate delivery, oral antihypertensive
treatment is indicated. Treatment with antihypertensive agents reduces the risk for severe AH, but not the risk for PE, restricted intrauterine growth, placental abruption and neonatal outcomes.20 Treatment to meet the DBP target of
85 mm Hg as compared to 100 mm Hg showed neither maternal nor obstetric benefit, except for the less frequent occurrence of severe AH in the group with stricter control.21

The choice of the antihypertensive drug depends on the
attending physician’s experience and familiarity with the
drug chosen and its possible side effects.22 (GR: IIb; LE:
B). The use of ACEIs, ARBs and direct renin inhibitors is
contraindicated in pregnancy (GR: I; LE: B), and atenolol
and prazosin should be avoided.22,23 (GR: IIa; LE: B). In
Brazil, the available oral drugs usually used are methyldopa,
BBs (except atenolol), hydralazine and CCBs (nifedipine,
amloidipine and verapamil). Atenolol is associated with
a reduction in fetal growth, and prazosin can cause
nativmortality.24-26 For PE, the prescription of a DIU is usually avoided; thiazide DIUs, however, can be continued in pregnant women with chronic AH (CAH),27 as long as they
do not cause volume depletion.

Magnesium sulfate is recommended for eclampsia
prevention and treatment. (GR: I; LE: B). In case of HE or of hypertensive urgency (HU) requiring hospitalization, intensive monitoring, preterm delivery and parenteral administration of antihypertensive drugs, the IV administration of magnesium sulfate, considered the drug of choice to prevent and treat eclampsia, is recommended.5,28-30 Magnesium sulfate is administered at an attack dose of 4-6 g IV for 10-20 minutes, followed by infusion of 1-3 g/h, usually for 24 hours. If the seizure recurs, 2-4 g can be administered
IV. Deep intramuscular administration of 10 g (5 g in each gluteus), followed by intramuscular 5 g every 4 hours for 24 hours is an alternative. Magnesium sulfate is indicated
during labor for patients with severe PE. Magnesium sulfate
administration should continue for up to 24 hours after seizure,
imminent eclampsia signs and delivery. Its administration
should be generous to patients with PE, preferably before the administration of rapid-acting antihypertensive drugs
to patients, in whom the possibility of eclampsia cannot be
ruled out.

**Other important aspects**

Severe AH, per se, is not an indication for C section. In
the presence of stable maternal clinical findings, good fetal
vitality and lack of other C section indications, pregnancy
termination can occur by delivery induction, always
considering maternal clinical condition and fetal vitality
during the procedure.3,29 Labor analgesia is recommended
with local-regional techniques (peridural or combined
analgesia). Severe thrombocytopenia contraindicates
anesthesia with lumbar puncture, and, if C section is
required, it should be performed under general anesthesia.
Invasive central monitoring is reserved to cases with
hemodynamic instability (respiratory failure, disseminated intravascular coagulation related to placental abruption, or HELLP syndrome).5

**Antihypertensive treatment in lactating women**

Chart 2 shows the antihypertensive drugs available in Brazil
considered safe, moderately safe and not recommended.31,32
(GR: IIb; LE: C).
### References

1. Abalos E, Cuesta C, Grosso A, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7.

2. Giordano JC, Parpinelli MA, Cecatti JG, Haddad SM, Costa ML, Sariá FG, et al. The burden of eclampsia: results from a multicenter study on surveillance of severe maternal morbidity in Brazil. PLoS One. 2014;9(5):e97401.

3. Caio DS, Schmidt MI, Duncan BB, Nucci LB, Matos MC, Branchtein L. Hypertensive disorders in pregnancy: frequency and associated factors in a cohort of Brazilian women. Hypertens Pregnancy. 2001;20(3):269-81.

4. Sass N, Silveira MR, Oliveira LG, Facca T, Sato JL, Korkes HA, et al. Maternal mortality in Brazil and proportion to hypertensive disorders: a trend of stagnation. Pregnancy Hypertens. 2015;5(1):78.

5. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(3):1122-31.

6. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2014 Jun 24;(6):CD001059.

7. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343(8898):619-29.

8. Duley L, Henderson-Damart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002252.

9. Captopril, enalapril and lisinopril. J Obstet Gynaecol Res. 2015;41(4):613-21.

10. Committee on Obstetric Practice. Committee on Obstetric Practice. Committee Opinion No. 592: Oral antihypertensive agents in pregnancy. Obstet Gynecol. 2015;125(2):521-5.

11. Martin NW, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246-54.

12. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1-203. Erratum in: BJOG. 2015;122(5):e1.

13. Meher S, Abalos E, Carroll G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003514.

14. Dowsell T, Middleton P, Weeks A. Antenatal day-care units versus hospital admission for women with complicated pregnancy. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD001803.

15. Koopmans CM, Bijlenga D, Groen H, Vijn VM, Aarnoudse MG, Bekedam DJ, et al. HYPTIT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPTIT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979-88.

16. Broekhuizen K, van Baaren JM, van Pampus MG, Ganzvoort W, Sikkema JM, Weiski MD, et al; HYPTIT-II study group. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPTIT-II): an open-label, randomised controlled trial. Lancet. 2015;385(9986):2492-501. Erratum in: Lancet. 2016;387(10021):848.

17. Ronsmans C, Campbell O. Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy. BMC Public Health. 2011;11 Suppl 3:38.

18. Meher S, Iwamoto CH, Silva MP, Torloni MR, Atallah NA. Does sodium nitroprusside kill babies? A systematic review. Sao Paulo Med J. 2007;125(2):108-11.

19. Imprey L. Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993;100(10):959-61.

20. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002252.

21. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(5):407-17.

22. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001449.
Guidelines

23. From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy – United States, Canada and Israel, 1987-1995. JAMA. 1997;277(15):1193-4.

24. Easterling TR, Carr DB, Brateng D, Diederichs C, Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol. 2001;98(3):427-33.

25. Easterling TR, Brateng D, Schmucker B, Brown Z, Millard SP. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol. 1999;93(5 Pt 1):725-33.

26. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomized control trial. BJOG. 2000;107(6):759-65.

27. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150(7):831-5.

28. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al; Maggie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Maggie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877-90.

29. Ministério da Saúde. Secretaria de Atenção à Saúde. Gestação de alto risco: manual técnico. 5a ed. Brasilia; 2012.

30. Sibai BM. Magnesium sulphate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190(6):1520-6.

31. Chaves RG, Lamounier JA, César CC. Medicines and breastfeeding: update and revision applied to mother and baby care. Rev Paul Pediatr. 2007;25(3):276-88.

32. Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Nefrologia. [VI Brazilian Guidelines on Hypertension]. Arq Bras Cardiol. 2010;95(1 Suppl):1-51. Erratum in: Arq Bras Cardiol. 2010;95(4):553.